Stockscreener 앱 받기
1.49
3.25%
-0.05
시간 외 거래:
1.47
-0.02
-1.34%
전일 마감가:
$1.54
열려 있는:
$1.53
하루 거래량:
805.47K
Relative Volume:
0.93
시가총액:
$161.14M
수익:
$27.08M
순이익/손실:
$-37.00M
주가수익비율:
-2.8654
EPS:
-0.52
순현금흐름:
$-18.46M
1주 성능:
-8.02%
1개월 성능:
-23.98%
6개월 성능:
+25.21%
1년 성능:
+19.20%
1일 변동 폭
$1.48
$1.585
1주일 범위
$1.46
$1.665
52주 변동 폭
$0.9515
$5.17
Aclaris Therapeutics Inc Stock (ACRS) Company Profile
명칭
Aclaris Therapeutics Inc
전화
484-324-7933
주소
701 LEE ROAD, WAYNE, PA
ACRS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ACRS
Aclaris Therapeutics Inc
|
1.49 | 161.14M | 27.08M | -37.00M | -18.46M | -0.52 |
|
TMO
Thermo Fisher Scientific Inc
|
470.03 | 177.32B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
197.90 | 141.59B | 23.88B | 3.90B | 5.30B | 5.28 |
|
IDXX
Idexx Laboratories Inc
|
410.76 | 33.29B | 3.90B | 887.87M | 798.08M | 10.67 |
|
A
Agilent Technologies Inc
|
109.67 | 31.28B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
167.69 | 29.57B | 15.41B | 1.37B | 2.11B | 7.50 |
Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-18 | 재개 | Cantor Fitzgerald | Overweight |
| 2024-12-23 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2024-11-20 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-19 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2024-11-19 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-11-19 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-11-18 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2024-01-22 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-11-13 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-10-03 | 개시 | Evercore ISI | Outperform |
| 2022-12-14 | 개시 | Stifel | Buy |
| 2022-12-01 | 개시 | Goldman | Buy |
| 2022-10-06 | 개시 | BTIG Research | Buy |
| 2021-07-23 | 재개 | Jefferies | Buy |
| 2021-06-15 | 개시 | Piper Sandler | Overweight |
| 2021-04-21 | 개시 | H.C. Wainwright | Buy |
| 2019-10-22 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-06 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-27 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2019-05-06 | 개시 | SVB Leerink | Outperform |
| 2018-03-28 | 재개 | Leerink Partners | Outperform |
| 2018-02-09 | 개시 | Guggenheim | Buy |
| 2017-06-16 | 개시 | Cantor Fitzgerald | Overweight |
| 2016-11-29 | 개시 | Leerink Partners | Outperform |
| 2016-09-30 | 개시 | JMP Securities | Mkt Outperform |
| 2016-06-10 | 개시 | Guggenheim | Buy |
| 2015-11-02 | 개시 | Citigroup | Buy |
| 2015-11-02 | 개시 | Jefferies | Buy |
모두보기
Aclaris Therapeutics Inc 주식(ACRS)의 최신 뉴스
Charles Schwab Investment Management Inc. Makes New Investment in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Sees Large Increase in Short Interest - Defense World
Brokerages Set Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Target Price at $11.67 - Defense World
Will Aclaris Therapeutics (NASDAQ:ACRS) Spend Its Cash Wisely? - Yahoo Finance
HighTower Advisors LLC Has $652,000 Position in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World
Aclaris at H.C. Wainwright Conference: Strategic Moves in Immuno-Inflammatory Diseases - Investing.com India
Aclaris Therapeutics Unveils Promising Data on ATI-2138, a Novel Dual ITK/JAK3 Inhibitor - MSN
Cantor Fitzgerald Has Weak Forecast for ACRS FY2025 Earnings - The AM Reporter
Aclaris Therapeutics ATM - Leerink Partners
Aclaris Therapeutics assumed with an Overweight at Cantor Fitzgerald - Yahoo Finance
Aclaris Therapeutics (NASDAQ:ACRS) Now Covered by Analysts at Cantor Fitzgerald - Defense World
Aclaris Reports 2024 Financial Results and Sets Stage for Transformative 2025 - MSN
Aclaris Therapeutics at Leerink’s Conference: Strategic Pipeline Expansion By Investing.com - Investing.com South Africa
Aclaris Therapeutics at Leerink’s Conference: Strategic Pipeline Expansion - Investing.com
Aclaris Therapeutics to Participate in Upcoming Healthcare Conferences - MSN
Common Warts Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, NDA Approvals, Medication, Prevalence, MOA, Revenue, Statistics and Companies by DelveInsight - The Globe and Mail
Scotiabank Begins Coverage on Aclaris Therapeutics (NASDAQ:ACRS) - Defense World
Aclaris Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Scotiabank Initiates Coverage of Aclaris Therapeutics (ACRS) with Sector Outperform Recommendation - Nasdaq
Scotiabank sets Aclaris stock target at $15 with new rating - Investing.com
Scotiabank sets Aclaris stock target at $15 with new rating By Investing.com - Investing.com UK
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Shares May Have Slumped 27% But Getting In Cheap Is Still Unlikely - Simply Wall St
Cantor Fitzgerald Predicts ACRS FY2025 Earnings - Defense World
Brokerages Set Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Price Target at $11.00 - Defense World
Aclaris Therapeutics (NASDAQ:ACRS shareholders incur further losses as stock declines 12% this week, taking three-year losses to 88% - Simply Wall St
Cantor Fitzgerald Upgrades Aclaris Therapeutics (NASDAQ:ACRS) to Strong-Buy - Defense World
Aclaris Therapeutics plans $300M mixed shelf offering - MSN
Aclaris Therapeutics to Participate in Two March Healthcare Conferences - GlobeNewswire
Will Aclaris Therapeutics Reveal New Pipeline Updates at March Healthcare Conferences? - StockTitan
This Aclaris Therapeutics Insider Increased Their Holding By 1,537% Last Year - Yahoo Finance
JAK Inhibitors Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight | DelveInsight - GlobeNewswire Inc.
Aclaris Therapeutics Inc (NASDAQ: ACRS): Hidden Gems In A Time Of Volatility - Stocks Register
Hair Loss Treatment Market Hits New High | Major Giants Follica, Theradome, Histogen, Aclaris Therapeutics - Newstrail
Q1 Earnings Forecast for ACRS Issued By Leerink Partnrs - Defense World
Aclaris Therapeutics (NASDAQ:ACRS) Posts Quarterly Earnings Results - MarketBeat
Investor Network: Aclaris Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Aclaris Therapeutics Reports 2024 Financial Results - TipRanks
Aclaris: Q4 Earnings Snapshot - CT Insider
Aclaris Therapeutics (ACRS) Reports Q4 Loss, Tops Revenue Estimates - MSN
Aclaris Therapeutics Inc earnings missed by $0.72, revenue topped estimates - Investing.com
Aclaris Therapeutics (NASDAQ:ACRS) Stock Price Passes Below 50 Day Moving AverageTime to Sell? - MarketBeat
Aclaris Therapeutics reports Q4 EPS ($1.01), consensus (38c) - TipRanks
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update - The Manila Times
Aclaris Therapeutics Announces New Employee Stock Grants Under 2024 Inducement Plan - MSN
Aclaris Therapeutics Inc (ACRS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.14%
1.59%
자본화:
|
볼륨(24시간):